Avadel Pharmaceuticals (NASDAQ:AVDL) Given Sell (E+) Rating at Weiss Ratings

Key Points

• Avadel Pharmaceuticals has been given a sell (E+) rating by Weiss Ratings, reflecting concerns about its stock performance.
• Despite the sell rating, several analysts have issued higher target prices and ratings for Avadel, with HC Wainwright raising its target from $24.00 to $36.00 and classifying it as a "buy."
• Avadel's recent quarterly report showed an earnings per share (EPS) of $0.10, beating estimates and indicating a significant revenue increase of 64.1% year-over-year.

Avadel Pharmaceuticals (NASDAQ:AVDL - Get Free Report)'s stock had its "sell (e+)" rating reaffirmed by Weiss Ratings in a report issued on Wednesday,Weiss Ratings reports.

A number of other analysts have also issued reports on AVDL. HC Wainwright increased their target price on Avadel Pharmaceuticals from $24.00 to $36.00 and gave the company a "buy" rating in a report on Friday, September 5th. Deutsche Bank Aktiengesellschaft restated a "buy" rating on shares of Avadel Pharmaceuticals in a report on Friday, August 8th. Zacks Research upgraded Avadel Pharmaceuticals to a "strong-buy" rating in a research note on Friday, August 8th. Lifesci Capital raised shares of Avadel Pharmaceuticals to a "strong-buy" rating in a research report on Wednesday, September 3rd. Finally, Wall Street Zen raised shares of Avadel Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Sunday, September 28th. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $20.86.

Avadel Pharmaceuticals Stock Down 1.8%

Shares of AVDL traded down $0.26 during trading on Wednesday, reaching $14.21. The company's stock had a trading volume of 1,393,437 shares, compared to its average volume of 1,359,711. The company has a market cap of $1.38 billion, a price-to-earnings ratio of -473.67 and a beta of 1.46. Avadel Pharmaceuticals has a twelve month low of $6.38 and a twelve month high of $16.66. The company has a fifty day moving average of $14.37 and a two-hundred day moving average of $10.86.

Avadel Pharmaceuticals (NASDAQ:AVDL - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $0.10 EPS for the quarter, topping analysts' consensus estimates of $0.02 by $0.08. Avadel Pharmaceuticals had a negative net margin of 1.32% and a negative return on equity of 3.73%. The firm had revenue of $68.13 million during the quarter, compared to the consensus estimate of $60.28 million. During the same quarter in the previous year, the company posted ($0.14) earnings per share. The firm's revenue was up 64.1% on a year-over-year basis. Avadel Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, equities analysts forecast that Avadel Pharmaceuticals will post -0.51 EPS for the current fiscal year.

Institutional Trading of Avadel Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. Nisa Investment Advisors LLC raised its holdings in shares of Avadel Pharmaceuticals by 164.5% in the 2nd quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company's stock valued at $29,000 after purchasing an additional 2,055 shares during the period. Raymond James Financial Inc. bought a new stake in shares of Avadel Pharmaceuticals during the second quarter worth approximately $65,000. Tower Research Capital LLC TRC boosted its holdings in shares of Avadel Pharmaceuticals by 217.5% during the second quarter. Tower Research Capital LLC TRC now owns 8,795 shares of the company's stock worth $78,000 after acquiring an additional 6,025 shares during the period. Thoroughbred Financial Services LLC bought a new stake in shares of Avadel Pharmaceuticals during the first quarter worth approximately $82,000. Finally, Exencial Wealth Advisors LLC bought a new position in Avadel Pharmaceuticals during the 1st quarter worth $82,000. Institutional investors own 69.19% of the company's stock.

Avadel Pharmaceuticals Company Profile

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.